Citations

Clear

6273 citation(s) found for "To, Andrew".

Subacute encephalitis with recovery in IgLON5 autoimmunity
McKeon, Andrew , Crum, Brian A. , McKeon, Andrew , Ramanan, Vijay K.

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | July 21, 2018 | Volume: 5 | Issue: 5 | Pages: No page available

10.1212/nxi.0000000000000485 | PMID 30175159 Get It

Subconjunctival Exposure to Carbopol Causes Chronic Histiocytic Inflammatory Response in Rabbits
Salomão, Diva R. , Iezzi, Raymond , Barkmeier, Andrew J. , Dalvin, Lauren A.

Mayo Clinic

Translational Vision Science & Technology | July 21, 2018 | Volume: 7 | Issue: 3 | Pages: 9

10.1167/tvst.7.3.9 | PMID 29876144 Get It

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Edwards, Marie E., Irazabal, María V. , Ofstie, Troy G., Bungum, Lisa A., Metzger, Andrew J., Senum, Sarah R. , Hogan, Marie C. , Kline, Timothy L. , Harris, Peter C. , Czerwiec, Frank S., Torres, Vicente E. , El-Zoghby, Ziad M, Kline, Timothy L , Harris, Peter C , Torres, Vicente E , Senum, Sarah R , Irazabal, Maria V , Chebib, Fouad T. , Zoghby, Ziad , Hogan, Marie C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 19, 2018 | Volume: 13 | Issue: 8 | Pages: 1153-1161

10.2215/cjn.01520218 | PMID 30026287 Get It

Background and objectives In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.6±2.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: ( 1 ) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; ( 2 ) Stability of eGFR slopes with duration of follow-up; and ( 3 ) comparison of observed and predicted eGFRs at last follow-up. Results Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD, −2.20±2.18 ml/min per 1.73 m 2 per year) and from month 1 (mean±SD, −1.97±2.44 ml/min per 1.73 m 2 per year) compared with controls (mean±SD, −3.50±2.09 ml/min per 1.73 m 2 per year; P <0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95% confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95% confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.
A Prognosis for Health Systems Science Courses: Observations From Current Students
Mastorakos, George , Richter, Kent R. , Asprey, Walker L., Pines, Andrew R. , Khurana, Aditya

Mayo Clinic

Academic Medicine | July 19, 2018 | Volume: 93 | Issue: 10 | Pages: 1434-1436

10.1097/acm.0000000000002369 | PMID 30024476 Get It

Certain medical schools have begun teaching courses in health systems science (HSS) to train medical students in skills aimed to improve health care in the United States. Although substantial research has been done on the potential benefit of HSS courses, reactions from students have not been reported. In this Invited Commentary, five medical students who have completed the first year of a longitudinal HSS course at the Arizona campus of the Mayo Clinic School of Medicine offer their observations of how early exposure to HSS affected their reactions to subsequent course work and current events in health care. The authors describe the HSS course and outline three benefits they have observed from their experience so far: (1) thinking more critically about health care delivery during all educational experiences, (2) gaining a better understanding of the complexity of the health care system, and (3) having a greater consideration for the many facets of health care delivery. The HSS course helped the authors identify health systems problems, develop solutions that incorporated diverse domains of health care delivery, and recognize the role and responsibility of the physician as an agent of change in a health care system.
Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study
Galli, Filippo , Nevala, Wendy K. , Paulsen, Andrew, Hung, Joseph C., Gansen, Denise N. , Marchetti, Paolo , Wiseman, Gregory A., Signore, Alberto , Paulsen, Andrew M, Markovic, Svetomir N. , Suman, Vera J. , Erickson, Lori A.

Mayo Clinic

Oncotarget | July 13, 2018 | Volume: 9 | Issue: 54 | Pages: 30268-30278

10.18632/oncotarget.25666 | PMID 30100988 Get It

Exome Chip Analysis Identifies Low-Frequency and Rare Variants in MRPL38 for White Matter Hyperintensities on Brain Magnetic Resonance Imaging
Jian, Xueqiu , Satizábal, Claudia L. , Smith, Albert V. , Wittfeld, Katharina , Bis, Joshua C. , Smith, Jennifer A. , Hofer, Edith , Mishra, Aniket , Adams, Hieab H.H. , Li, Shuo , Teumer, Alexander , Zhao, Wei , Saba, Yasaman , Yanek, Lisa R. , Chauhan, Ganesh , Buchem, Mark A. van , Royle, Natalie A., Niessen, Wiro J. , Windham, B. Gwen , DeStefano, Anita L. , Habes, Mohamad , Heckbert, Susan R. , Palmer, Nicholette D., Lewis, Cora E. , Eiríksdóttir, Guðný , Maillard, Pauline , Mathias, Rasika A. , Divers, Jasmin, Beiser, Alexa S., Langner, Sönke , Rice, Kenneth , Bastin, Mark E. , Starr, John M. , Sidney, Stephen , Risacher, Shannon L. , Uitterlinden, André G. , Guðnason, Vilmundur , Rotter, Jerome I. , Schreiner, Pamela J. , Boerwinkle, Eric , Duijn, Cornelia M. van , Sarnowski, Bettina von , Gottesman, Rebecca F., Levy, Daniel , Sigurðsson, Sigurður , Vernooij, Meike W. , Schmidt, Reinhold, Wardlaw, Joanna M. , Mosley, Thomas H. , DeCarli, Charles , Bowden, Donald W. , Becker, Diane M. , Deary, Ian J. , Schmidt, Helena , Kardia, Sharon L. R., Debette, Stéphanie , Longstreth, W.T. , Seshadri, Sudha , Launer, Lenore J. , Fornage, Myriam , Group, for the neuroCHARGE Working, Dichgans, Martin , Rice, Kenneth , Palmer, Nicholette D. , DeCarli, Charles , Turner, Stephen T. , Dichgans, Martin , Wardlaw, Joanna Marguerite , Smith, Jennifer A , Adams, Hieab H H , Satizabal, Claudia L , Seshadri, Sudha , Bastin, Mark E , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Smith, Albert V , Palmer, Nicholette D , Rotter, Jerome I , Mathias, Rasika A , Rice, Ken , Levy, Daniel , Hsu, Fang‐Chi , Nho, Kwangsik T. , Hagenaars, Saskia P. , Nyquist, Paul , Freedman, Barry I. , Cushman, Mary , Bryan, Robert Nick , Homuth, Georg , Hernández, Maria del Carmen Valdés , Divers, Jasmin , Yang, Qiong , Maldjian, Joseph A. , Nauck, Matthias A. , Mazoyer, Bernard , Psaty, Bruce M. , Saykin, Andrew J. , Ikram, M. Arfan , Grabe, Hans Jörgen , Group, for the neuroCHARGE Working, Maillard, Pauline

Mayo Clinic

Stroke | July 12, 2018 | Volume: 49 | Issue: 8 | Pages: 1812-1819

10.1161/strokeaha.118.020689 | PMID 30002152 Get It

Background and Purpose— White matter hyperintensities (WMH) on brain magnetic resonance imaging are typical signs of cerebral small vessel disease and may indicate various preclinical, age-related neurological disorders, such as stroke. Though WMH are highly heritable, known common variants explain a small proportion of the WMH variance. The contribution of low-frequency/rare coding variants to WMH burden has not been explored. Methods— In the discovery sample we recruited 20 719 stroke/dementia-free adults from 13 population-based cohort studies within the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, among which 17 790 were of European ancestry and 2929 of African ancestry. We genotyped these participants at ≈250 000 mostly exonic variants with Illumina HumanExome BeadChip arrays. We performed ethnicity-specific linear regression on rank-normalized WMH in each study separately, which were then combined in meta-analyses to test for association with single variants and genes aggregating the effects of putatively functional low-frequency/rare variants. We then sought replication of the top findings in 1192 adults (European ancestry) with whole exome/genome sequencing data from 2 independent studies. Results— At 17q25, we confirmed the association of multiple common variants in TRIM65 , FBF1 , and ACOX1 ( P <6×10 −7 ). We also identified a novel association with 2 low-frequency nonsynonymous variants in MRPL38 (lead, rs34136221; P EA =4.5×10 −8 ) partially independent of known common signal ( P EA(conditional) =1.4×10 −3 ). We further identified a locus at 2q33 containing common variants in NBEAL1 , CARF , and WDR12 (lead, rs2351524; P all =1.9×10 −10 ). Although our novel findings were not replicated because of limited power and possible differences in study design, meta-analysis of the discovery and replication samples yielded stronger association for the 2 low-frequency MRPL38 variants ( P rs34136221 =2.8×10 −8 ). Conclusions— Both common and low-frequency/rare functional variants influence WMH. Larger replication and experimental follow-up are essential to confirm our findings and uncover the biological causal mechanisms of age-related WMH.
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery
Chung, Caroline , Bryant, Andrew , Brown, Paul D.

Mayo Clinic

Cochrane Database of Systematic Reviews | July 10, 2018 | Volume: 2018 | Issue: 7 | Pages: No page available

10.1002/14651858.cd011492.pub2 | PMID 29987845 Get It

Autoimmune septin-5 cerebellar ataxia
Honorat, Josephe A., López‐Chiriboga, A. Sebastian , Kryzer, Thomas J., Fryer, James P., Devine, Michelle F., Flores, Angela, Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Devine, Michelle, Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | July 9, 2018 | Volume: 5 | Issue: 5 | Pages: No page available

10.1212/nxi.0000000000000474 | PMID 29998156 Get It

Intraoperative use of low volume ventilation to decrease postoperative mortality, mechanical ventilation, lengths of stay and lung injury in adults without acute lung injury
Guay, Joanne, Ochroch, E. Andrew, Kopp, Sandra L.

Mayo Clinic

Cochrane Database of Systematic Reviews | July 9, 2018 | Volume: 2018 | Issue: 10 | Pages: No page available

10.1002/14651858.cd011151.pub3 | PMID 29985541 Get It